GlassScriptPhysician profile
Ashleigh T Bars
NPI 1356759948
$2,312.59
in general payments reported to CMS, 2019-2025
32 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $700 · 2022: $215 · 2023: $415 · 2024: $546 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $819.59 | 2021-2025 | |
| Biogen, INC. | $146.08 | 2021-2024 | Spinraza |
| Pfizer INC. | $137.72 | 2023-2025 | |
| Medtronic, INC. | $125.17 | 2021-2024 | Synchromedii, Vanta Adaptivestim, Intellis Adaptivestim |
| Ipsen Biopharmaceuticals, INC | $119.18 | 2021-2025 | Dysport |
| Boston Scientific Corporation | $118.34 | 2021-2025 | Intracept, Filterwire Ez |
| Sunovion Pharmaceuticals INC. | $76.94 | 2021 | |
| Acadia Pharmaceuticals INC | $72.22 | 2021 | |
| Allergan, INC. | $68.16 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.02 | 2023-2025 | Relistor |
| Averitas Pharma INC. | $60.82 | 2024-2025 | Qutenza |
| Stryker Corporation | $45.36 | 2025 | Limflow System |
| Saluda Medical Americas, INC. | $38.76 | 2023-2024 | Evoke Scs, Evoke |
| Genentech USA, INC. | $35.47 | 2021-2022 | |
| Lilly USA, LLC | $33.25 | 2023-2024 | Emgality, Reyvow |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $32.99 | 2021 | |
| Itf Therapeutics LLC | $32.94 | 2025 | |
| Amgen INC. | $27.50 | 2022 | |
| Impel Pharmaceuticals INC. | $23.92 | 2022 | |
| Ns Pharma, INC. | $21.91 | 2023 | Viltepso |
| Csl Behring | $21.44 | 2021 | |
| Abbott Laboratories | $21.37 | 2021 | |
| Neurocrine Biosciences, INC. | $20.71 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.00 | 2023 | Amvuttra |
| Tanabe Pharma America, INC. | $18.07 | 2023 | |
| Acorda Therapeutics, INC | $17.76 | 2021 | |
| Kyowa Kirin, INC. | $16.91 | 2024 | Nourianz |
| Sk Life Science, INC. | $16.41 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $15.79 | 2024 | |
| Neurelis, INC. | $14.75 | 2021 | |
| Merz Pharmaceuticals, LLC | $14.09 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashleigh Bars listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.